Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach
Jin Liu, Ronald A Faris
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates in order to predict in vivo outcomes of safety risk and therapeutic efficiency. Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by pharmaceutical industry HepatoCells have shown mature hepatocyte-like morphology, demonstrated primary hepatocyte-like response to prototypical inducers of all 3 CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital responsive nuclear translocation of human CAR from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and non-inducers. A relative induction score (RIS) calibration curve based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.
https://dmd.aspetjournals.org/content/early/2017/01/06/dmd.116.072124
https://dmd.aspetjournals.org/content/dmd/early/2017/01/06/dmd.116.072124.full.pdf
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.
Fa2N-4 Multicell Technologies / Xenotech Patents
Inventor: Jin Liu, Ronald A Faris
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161330062
Let's look at it that way, maybe the company will make a profit and before pr comes the company will buy back shares via MMs.
Let's see what the future brings.
Twitter waking up... whatever that means
https://twitter.com/search?q=%24mcet&src=typeahead_click&f=live
So you have to read the fine print. Liberty Capital Group.!
Is there anything coming soon for the confirmation and news?
About Fa2N-4: NOTE 5. RESEARCH AND LICENSE AGREEMENTS
Last FORM 10-Q August 31, 2015. https://www.sec.gov/Archives/edgar/data/811779/000161577415002935/s101959_10q.htm
Corning Incorporated
The Company has an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell the Company’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (“ADME/Tox assays”). The Company retained and will continue to support all of its existing licensees. The Company retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. The Company also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to produce therapeutic proteins using the Company’s BioFactories™ technology, to identify drug targets and for other applications related to the Company’s internal drug development programs. In consideration for the license granted, Corning paid the Company $750,000. The Company is recognizing the income ratably over a 17-year period. The Company recognized $11,029 and $33,088, respectively, in income for each of the three months and nine months ended August 31, 2015 and 2014. The balance of deferred revenue from this license was $400,736 and $433,824 at August 31, 2015 and November 30, 2014, respectively, and will be amortized into revenue through October 2024.
Pfizer Inc.
The Company has another license agreement with Pfizer Inc. (“Pfizer”), for which revenue is being deferred. The Company recognized $1,300 and $3,900, respectively, in income for each of the three months and nine months ended August 31, 2015 and 2014. The balance of deferred revenue from this license was $11,700 and $15,600 at August 31, 2015 and November 30, 2014, respectively, and will be amortized into revenue through January 2018.
MultiCell Technologies Inc. Signs Worldwide Exclusive License Agreement With Corning Incorporated https://www.biospace.com/article/releases/multicell-technologies-inc-signs-worldwide-exclusive-license-agreement-with-corning-incorporated-/
Info about Multicell Fa2N-4 License partner SEKISUI XENOTECH: https://www.xenotech.com/about/history/
Idglobal Corp. Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
Great! New info about $IDGC???
$MCET $TRONG HOLD! More Big Buys on ask coming! ON Breakout Board!
$MCET $TRONG HOLD! More Big Buys on ask coming! ON Breakout Board!
LA JOLLA COVE INVESTORS, INC earns very well! They have Outstanding Shares OS 499,594,775 9.99% from MCET Multicell Technologies.
2019-02-14
https://www.sec.gov/Archives/edgar/data/811779/000114420419007520/tv513409_sc13ga.htm
$MCET 0.0008 +6.67% Volume: 423,876,993 ON BREAKOUT BOARD $$$$$$
$MCET 0.0008 +6.67% Volume: 423,876,993 ON BREAKOUT BOARD $$$$$$
$GSFI Green Stream Holdings Anticipates Sunny Forecast for Renewable Energy - Market Rally as U.S. Stocks Soar Just Hours Before Biden Inauguration
JAN 20, 2021 11:59AM EST
Malibu, California--(Newsfile Corp. - January 20, 2021) - Green Stream Holdings Inc. (OTC PINK: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com ), an emerging leader in the solar utility and finance space, announces today what it believes to be a new era for Renewable Energy and its Solar Utilities/Financing model as stocks rise in advance of the inauguration of Joe Biden as the 46th President of the United States.
To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_002full.jpg
Biden's agenda is to transition the U.S. from an economy reliant on fossil fuels to one driven by wind, solar and other renewable-energy sources. The shift from fossil-fuel companies to renewable-energy firms accelerated during the Trump administration, despite the president's vows to support the U.S. coal and petroleum industries.
Big and small investors have moved their assets away from fossil-fuel producers and toward renewable energy companies. Big investors like BlackRock Inc., the world's largest asset manager, overseeing $7.8 trillion, have said they plan to take into account corporations' disclosures of environmental risks, including carbon footprints.
According to Wells Fargo senior market strategist Scott Wren, "Since the start of the year, cyclicals have outperformed, with energy gaining the most, up 15%, helped by higher oil prices. Financials were up 5.1%, and materials were up 4.4%."
"All of these cyclicals stocks have moved in advance of what we think will be a higher rate move. Rates have moved up to support that idea," Wilson said. "We think they could go up quite a bit more over the course of the next several months."
As well, The iShares Global Clean Energy ETF, which tracks S&P Global's index of clean energy companies around the world, has risen by nearly 30% since July 2020. The fund's assets under management swelled to $1.2 billion from $431 million at the start of the year.
GSFI CEO Eric Fain is encouraged by the increased opportunity Biden's new agenda could mean for companies like Green Stream Holdings. "I believe we are at the dawn of a new era for renewable energy and, in turn, an increased access to market with ability to expedite shareholder value as we cultivate new opportunities alongside our current projects in New York, including:
160 Imlay street. Brooklyn Ny
8012 Tonelle Ave; North Bergen, NJ
44 Victory Blvd; Staten Island, NY
111 Station Road; Bellport, NY
15-17 Sherwood Ave - Yonkers Proposal
4290 Austin Blvd; Island Park, NY
"We have recently moved our headquarters to a functional work/living space which belongs to our flagship project at 160 Imlay Street in Brooklyn, New York, where our utility/financing model can be seen in action as we continue to develop opportunities in the NE United States and beyond."
Project To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_003full.jpg
"This is all in line with NY Governor Cuomo's recent announcement of a clean energy initiative which unveiled the details of the awards for 21 large-scale solar, wind, and energy storage projects across upstate New York, totaling 1,278 megawatts of new renewable capacity," states Fain.
Shareholders-visit greenrainsolar.com. where you can view Green Stream's news, filings and even a live Level 2 stream, along with other company information.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004.jpg GSFI - Strategic Moves To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004full.jpg
https://www.nasdaq.com/press-release/green-stream-holdings-anticipates-sunny-forecast-for-renewable-energy-market-rally-as
$GSFI Green Stream Holdings Anticipates Sunny Forecast for Renewable Energy - Market Rally as U.S. Stocks Soar Just Hours Before Biden Inauguration
JAN 20, 2021 11:59AM EST
Malibu, California--(Newsfile Corp. - January 20, 2021) - Green Stream Holdings Inc. (OTC PINK: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com ), an emerging leader in the solar utility and finance space, announces today what it believes to be a new era for Renewable Energy and its Solar Utilities/Financing model as stocks rise in advance of the inauguration of Joe Biden as the 46th President of the United States.
To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_002full.jpg
Biden's agenda is to transition the U.S. from an economy reliant on fossil fuels to one driven by wind, solar and other renewable-energy sources. The shift from fossil-fuel companies to renewable-energy firms accelerated during the Trump administration, despite the president's vows to support the U.S. coal and petroleum industries.
Big and small investors have moved their assets away from fossil-fuel producers and toward renewable energy companies. Big investors like BlackRock Inc., the world's largest asset manager, overseeing $7.8 trillion, have said they plan to take into account corporations' disclosures of environmental risks, including carbon footprints.
According to Wells Fargo senior market strategist Scott Wren, "Since the start of the year, cyclicals have outperformed, with energy gaining the most, up 15%, helped by higher oil prices. Financials were up 5.1%, and materials were up 4.4%."
"All of these cyclicals stocks have moved in advance of what we think will be a higher rate move. Rates have moved up to support that idea," Wilson said. "We think they could go up quite a bit more over the course of the next several months."
As well, The iShares Global Clean Energy ETF, which tracks S&P Global's index of clean energy companies around the world, has risen by nearly 30% since July 2020. The fund's assets under management swelled to $1.2 billion from $431 million at the start of the year.
GSFI CEO Eric Fain is encouraged by the increased opportunity Biden's new agenda could mean for companies like Green Stream Holdings. "I believe we are at the dawn of a new era for renewable energy and, in turn, an increased access to market with ability to expedite shareholder value as we cultivate new opportunities alongside our current projects in New York, including:
160 Imlay street. Brooklyn Ny
8012 Tonelle Ave; North Bergen, NJ
44 Victory Blvd; Staten Island, NY
111 Station Road; Bellport, NY
15-17 Sherwood Ave - Yonkers Proposal
4290 Austin Blvd; Island Park, NY
"We have recently moved our headquarters to a functional work/living space which belongs to our flagship project at 160 Imlay Street in Brooklyn, New York, where our utility/financing model can be seen in action as we continue to develop opportunities in the NE United States and beyond."
Project To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_003full.jpg
"This is all in line with NY Governor Cuomo's recent announcement of a clean energy initiative which unveiled the details of the awards for 21 large-scale solar, wind, and energy storage projects across upstate New York, totaling 1,278 megawatts of new renewable capacity," states Fain.
Shareholders-visit greenrainsolar.com. where you can view Green Stream's news, filings and even a live Level 2 stream, along with other company information.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004.jpg GSFI - Strategic Moves To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004full.jpg
https://www.nasdaq.com/press-release/green-stream-holdings-anticipates-sunny-forecast-for-renewable-energy-market-rally-as
Contact Information Multicell Technologies!
Contact Information
Phone(s)
401-762-0045
Fax(es)
401-762-0098
Email(s)
lgomes@multicelltech.com
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481x3
NCAGE Code 481X3MULTICELL TECHNOLOGIES INC.
CAGE Code 481X3MULTICELL TECHNOLOGIES, INC. ]
DUNS 173651688MULTICELL TECHNOLOGIES, INC.
SEC 0001363980Multicell Technologies Inc
SEC 0000811779MultiCell Technologies, Inc.
NCAGE Code Registration Status A - Active record
Last Updated 2020-02-26 04:18:07
Status Code 0
Foreign/Domestic Designator Code : US F/DDC 1
Type Code 4
Country UNITED STATES
Phone Contacts 401-762-0045
Email Contacts lgomes@multicelltech.com
FAX Numbers 401-762-0098
NAICS Codes 541711
Address 68 CUMBERLAND ST STE 301
WOONSOCKET, RI UNITED STATES
02895-3332
Geo Address City and Postal WOONSOCKET 02895-3332
https://cage.report/NCAGE/481X3
#39 MultiCell Technologies (MCET) ON BB!
Please Read! What is Multicell Technologies' stake with an average unit sales of 20,000 units and an average price of $ 631 dollars per year???
For example: 20,000 units * $631 dollars = $12,620,000 dollars per year.
Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
Multicell Technologies raised at what price ??? Because of the ...
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
DEF 14A Filing Date 2014-12-12 https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders of MultiCell Technologies, Inc., a Delaware corporation (the “Company”). The meeting will be held on January 22, 2015, at 1:30 p.m. local time at the offices of Procopio, Cory, Hargreaves & Savitch LLP, One Del Mar, 12544 High Bluff Drive, Suite 300, San Diego, CA 92130, for the following purposes:
1. To elect directors to serve for the ensuing year and until their successors are elected.
2. To ratify the selection by the Audit Committee of the Board of Directors of the Company of Eide Bailly LLP as the Company’s Independent Registered Public Accounting Firm for its fiscal year ending November 30, 2014.
3. To approve an amendment to the Amended and Restated Certificate of Incorporation, as amended, to effect an increase in the number of authorized shares of the Company’s common stock to a total of 10 billion shares.
4. To approve the Company’s 2014 Equity Incentive Plan.
5. To conduct any other business properly brought before the meeting.
These items of business are more fully described in the Proxy Statement accompanying this Notice.
The record date for the Annual Meeting is November 24, 2014. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.
PATENT INFORMATION
======================================
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=86202825
Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.
MultiCell Technologies, Inc.
US Patent 6,737,057: Compounds, compositions and methods for the Endocytic presentation of immunosuppressive factors
US Patent 6,129,911: Liver stem cell
US Patent 6,872,389: Liver stem cell
US Patent 6,017,760: Isolation and culture of porcine hepatocytes
US Patent 6,107,043: Immortalized hepatocytes
US Patent 5,043,260: Perfusion device with hepatocytes
US Patent 4,795,459: Implantable Prosthetic Device (endothelial)
US Patent 6,858,146: Artificial Liver Apparatus and Method (Trademarked as the SybiolR synthetic bio-liver)
US Patent 7,935,528 The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
US Patent 7,566,567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1:
IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1685252A4: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
WO05034876A2 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2541380A1 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins
Xenogenics.
When Xenogenics acquired the assets of Bioabsorbable Therapeutics, Inc., it acquired and continues to support issued U.S. patent 7,674,285: Polyanhydride polymers and their uses in biomedical devices. This process is incorporated in and trademarked as the Ideal Bio-StentR.
MultiCell ImmunoTherapeutics.
Below is a listing of the intellectual properties of which Astral, Inc. is the Assignee. This intellectual property is now owned by MultiCell Immunotherapeutics resulting from the purchase agreement between MultiCell Technologies, Inc. and Alliance Pharmaceuticals, Inc.
US20120189645A1:COMPOSITIONS AND METHODS TO TREAT AND CONTROL TUMORS.
CN100376594C: DOUBLE-CHAIN RNA AND METHOD TO INITIATE, ENHANCE OR ADJUST IMMUNOMODULATORY OR IMMUNE RESPONSE.
CN1795274A: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CN1780848A: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND
MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY
USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
WO04087877A3: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CN1703427A: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS .
WO04087877A2: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
WO04027049B1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO04027049A3: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595B1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
WO04027049A2: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A3: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
CA2520181A1: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CA2499066A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
AU4225480A1: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
AU3276932A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A2: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY
USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
CA2479187A1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
AU3218181A1: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
US7566567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1:
IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1685252A4: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
WO05034876A2 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2541380A1 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins
Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
$MCET .0008 +6.67% Volume: 352,716,067 More Huge BIG BLOCKS BUYS here!
$MCET .0008 +6.67% Volume: 352,716,067 More Huge BIG BLOCKS BUYS here!
Thats HUGE VOLUME BUY! Many BIG BUYS HERE! $$$$$
$MCET VOLUME DIP BUY)))))) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161327504
$MCET VOLUME DIP BUY)))))) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161327504
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Nice start volume, it is cleaned.
$MCET Great Income per year! Look here! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161288888
$MCET Great Income per year! Look here! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161288888
Market Makers on radar! LONG confirmed! More and More VOLUME! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/